Gene therapy hope for babies with fatal brain disease

NCT ID NCT04411654

First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests a single-dose gene therapy (LY3884961) in 7 infants with Type 2 Gaucher disease, a severe and life-limiting condition. The treatment aims to correct the genetic defect to slow or stop disease progression. Researchers will monitor safety, side effects, and how well the therapy works over 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GAUCHER DISEASE, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital of Pittsburgh, 4401 Penn Avenue

    Pittsburgh, Pennsylvania, 15224, United States

  • Lysosomal & Rare Disorders Research and Treatment Center

    Fairfax, Virginia, 22030, United States

  • Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Oxford Road

    Manchester, M13 9WL, United Kingdom

  • UCSF Benioff Children's Hospital, 747 52nd St

    Oakland, California, 94609, United States

  • University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue

    Minneapolis, Minnesota, 55454, United States

Conditions

Explore the condition pages connected to this study.